Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 33,170 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Bladder Cancer
Interventions: Rapamycin, Placebo Oral Tablet; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Parkinson Disease
Interventions: AP-472, Placebo; Drug · Other
Lead sponsor: Appello Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 30
States / cities: Little Rock, Arkansas • Carlsbad, California • Los Alamitos, California + 25 more

Conditions: Obstructive Sleep Apnea (OSA)
Interventions: Placebo oral capsule, DAW2020 oral capsule; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Thyroid Cancer
Interventions: XL184, Placebo; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 29
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 26 more

Conditions: Obesity, Diabetes Mellitus, Type 2
Interventions: Survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 34
States / cities: Anniston, Alabama • Phoenix, Arizona • Spring Valley, California + 31 more

Conditions: Sickle Cell Disease
Interventions: Dronabinol, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: ST Segment Elevation Myocardial Infarction
Interventions: NBS10, placebo; Biological · Other
Lead sponsor: Lisata Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 58
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 50 more

Conditions: Postoperative Ileus
Interventions: Daikenchuto (TU-100), Placebo; Drug
Lead sponsor: Tsumura USA; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 13
States / cities: Los Angeles, California • Aurora, Colorado • Weston, Florida + 10 more

Conditions: Constipation
Interventions: B. lactis HN019, Placebo; Dietary Supplement
Lead sponsor: Fonterra Research Centre; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 12
States / cities: Glendale, Arizona • Encinitas, California • Garden Grove, California + 8 more

Conditions: Coronary Artery Disease
Interventions: Clopidogrel, Placebo; Drug
Lead sponsor: Deutsches Herzzentrum Muenchen; Other
Eligibility: 18 Years and older
Enrollment: 4,005 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Focus of the Study: Safety of XFB19
Interventions: XFB19, Placebo; Drug
Lead sponsor: Xfibra, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Central Centrifugal Cicatricial Alopecia
Interventions: Platelet-Rich Plasma (PRP) Injections, Saline; Biological · Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Heart Failure
Interventions: Vasopressin V2 Receptor Antagonist; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 7
States / cities: Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 4 more

Conditions: Attention Deficit Disorder With Hyperactivity, Epilepsy
Interventions: Extended Release Methylphenidate (OROS-Methylphenidate); Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years to 18 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Atherosclerosis
Interventions: Placebo, TriLipix; Drug
Lead sponsor: Piedmont Healthcare; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: Activin ligand-trap biological therapy, Placebo, Normal Saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Kidney Transplant Recipients
Interventions: Multivitamin, Placebo; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Antioxidant, Placebo; Dietary Supplement · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 75 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Blepharitis
Interventions: Pimecrolimus 0.3% Ophthalmic Ointment, Placebo Ophthalmic Ointment; Drug
Lead sponsor: Famy Life Sciences, a Viatris Company; Industry
Eligibility: 2 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 29
States / cities: Pheonix, Arizona • Garden Grove, California • Glendale, California + 26 more

Conditions: Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
Interventions: PF-06817024, Placebo for PF-06817024; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 20
States / cities: Sacramento, California • New Haven, Connecticut • Shelton, Connecticut + 12 more

Conditions: Friedreich's Ataxia
Interventions: Placebo, EPI-743 400 mg, EPI-743 200 mg; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Tampa, Florida • Philadelphia, Pennsylvania

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Phoenix, Arizona • Anaheim, California • San Diego, California + 9 more

Conditions: Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions: GSK1838262 Extended Release Tablets, Placebo; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 24
States / cities: Jasper, Alabama • San Diego, California • Hallandale, Florida + 20 more

Conditions: Obstructive Sleep Apnea
Interventions: Acetazolamide, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

DAW2020 on OSA Endotypic Traits

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain

NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction

Effect of TU-100 in Patients Undergoing Laparoscopic Colectomy

B. Lactis HN019 for Functional Constipation

Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting

A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.

Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia

Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).

Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy

AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis

EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)

A Multivitamin Comparison Study in Kidney Transplant Recipients.

Racial and Aging Effects of Acute Antioxidant Supplementation

A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance

Patient-centered and Neurocognitive Outcomes With Acetazolamide for Sleep Apnea